Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Ingelheim am Rhein, Germany and Geneva, Switzerland – 15 July 2019 – Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.

PDF icon View PDF The AMAL Team

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL:

OK